We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Biomarker Predicts Response to Therapy in Patients with a Rare Form of Metastatic Colorectal Cancer

By LabMedica International staff writers
Posted on 29 Sep 2022
Print article
Image: BRAF, a protein involved in sending signals inside cells which are involved in directing cell growth, is mutated in some human cancers (Photo courtesy of www.123rf.com)
Image: BRAF, a protein involved in sending signals inside cells which are involved in directing cell growth, is mutated in some human cancers (Photo courtesy of www.123rf.com)

Cancer researchers have identified a biomarker that predicts response of patients with microsatellite stable BRAF V600E metastatic colorectal cancer (MSS mCRC) to treatment with combined anti-BRAF/EGFR therapy.

Microsatellites are repeated sequences of DNA. These sequences can be made of units of one to six base pairs in length that are repeated and reside adjacent to each other in the genome. Although the length of microsatellites can vary from person to person and contributes to the individual DNA "fingerprint", each individual has microsatellites of a set length.

Mutations in BRAFV600E occur in around 10% of mCRC, and while relatively rare, they associate with a poor prognosis. Since a large fraction of mCRC patients do not respond to the recently approved combined anti-BRAF/EGFR therapy, there is an urgent need to identify the molecular determinants of treatment response.

In this regard, investigators at Vall d'Hebron Institute of Oncology (Barcelona, Spain) used whole-exome sequencing and targeted next generation sequencing (NGS) to analyze a discovery cohort of patients with mCRC(BRAF-V600E) treated with anti-BRAF/EGFR therapy. In addition, a control cohort of patients with mCRC(BRAF-V600E) receiving standard chemotherapies and anti-angiogenic agents (and not exposed to anti-BRAF) was evaluated. Data obtained from the molecular analyses were integrated with clinical correlates of response and survival.

Results revealed that inactivating mutations in RNF43, a negative regulator of the WNT signaling pathway, predicted improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. The response rate among patients with a BRAFV600E MSS mCRC carrying a RNF43 mutation reached 72.7%, and only 30.8% in those without the mutation. In patients with tumors harboring the RNF43 mutation, median disease-free progression was 10.1 months versus 4.1 months and overall survival in the former was 13.6 months compared to seven months in the latter.

The investigators concluded that patients with MSS-mCRC(BRAF-V600E) tumors harboring loss-of-function mutations in RNF43 responded favorably to combined anti-BRAF/EGFR therapy, whereas those with functional RNF43 derived limited benefit from this treatment.

"We performed extensive genomic analysis of over 20,000 genes. In total, we analyzed data from 166 patients which represents a significant number considering the rarity of this tumor subtype that accounts for around 10% of all colorectal cancers," said senior author Dr. Rodrigo A. Toledo, a translational investigator at Vall d'Hebron Institute of Oncology. "Our data point to RNF43 as a potential stratification biomarker that could help steer treatment decision making as well as define the optimal sequence of treatment in patients with microsatellite stable, BRAF V600E- mutant metastatic colorectal cancer. As importantly, it could also help to identify those patients for whom alternative treatment options are very much needed."

The study was published in the September 12, 2022, online edition of the journal Nature Medicine.

Related Links:
Vall d'Hebron Institute of Oncology 

Gold Supplier
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
New
4K Lite Ultra HD Camera
UHD-4K Lite Camera
New
Sepsis Test
MM SEPSIS PANEL
New
Cellular Allergen Stimulation Test
CAST ELISA

Print article
SUGENTECH INC.

Channels

Clinical Chem.

view channel
Image: Equivalence of Genetically Elevated LDL and Lipoprotein(a) on Myocardial Infarction (Photo courtesy of Viborg Regional Hospital)

Familial Hypercholesterolemia Patients With ACD Have Elevated Lipoprotein(a)

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL cholesterol), in the blood and early cardiovascular... Read more

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Pathology

view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.